CClinicalTrials.gg
CompletedNCT03370068ICSIUpdated Jul 28, 2020

The Role of ICSI in Non-male Factor Infertility in Advanced Maternal Age

An interventional study of ICSI and Conventional IVF in Infertility, Female, sponsored by Dr. Tal Miller-Elkan. Completed at 1 site in Israel. Open to female participants aged 39 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-28.

Sponsored by Dr. Tal Miller-Elkan · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
39 Years to 44 Years
Sex
Female
01

Study summary

The use of Intracytoplasmic sperm injection (ICSI) has increased in the last decades regardless of the cause of infertility. Despite the increased use there is no clear evidence that ICIS is more effective than conventional in vitro fertilization (IVF) for non-male factor infertility. The investigators therefore aim to perform a prospective randomized controlled study to compare between ICSI and conventional IVF in women between 39 to 44 years of age with non-male factor infertility.

Read the detailed description

ICSI is a method used in IVF in which a single sperm is injected directly into an oocyte. Originally ICSI was developed as a method for the treatment for couples with severe male factor infertility. In the last decades the use of ICSI has increased dramatically, especially for non-male factor infertility. In certain fertility clinics in the world ICSI is conducted in 100% of IVF cycles.

Despite the increased use of ICSI, there is no clear evidence that ICIS is more effective than conventional IVF for non-male factor infertility. There are currently few randomized controlled studies that compared the two modalities in the case of non-male factor infertility. In a randomized controlled trial that included 415 couples with non-male factor infertility and women younger than 37 years of age, conventional IVF was associated with better fertilization and implantation rates than ICSI but with comparable live birth rates. In addition, studies have not shown an advantage for ICSI over conventional IVF in the case of unexplained infertility, low oocyte yield or routine use to decrease the incidence of fertilization failure.

The proportion of women after the age of 35 undergoing IVF is constantly on the rise. Oocytes retrieved from older women are often of lower quality then oocytes retrieved from younger women. It is believed that due to the lower quality the fertilization rate is decreased in this population. However a recently published retrospective study including 745 women did not show an advantage for ICSI over conventional IVF. Contrary to what is believed, the conventional IVF group had a higher number of zygotes formed, more cycles with embryos transferred at the blastocyst stage and more cycles where embryos were available for cryopreservation.

The investigators therefore aim to perform a prospective randomized controlled study to compare between ICSI and conventional IVF in women between 39 to 44 years of age with non-male factor infertility. Male-factor infertility will be diagnosed according to the accepted semen analysis values included a semen concentration of 200 million/mL, progressive motility of 40% and a strict morphology of 4%. Patients will undergo standard clinical and hormonal investigation as usual for IVF. The treatment protocol will be in accordance with the decision of the attending physician, regardless of the research. Randomization will be between the ovaries of each patient. Following an informed consent a computer based randomization will allocate either ICSI or conventional IVF for each ovary so that for each study participant oocyte from one ovary will be randomly allocated to insemination by ICSI and the oocytes from the other ovary will be allocated to insemination by conventional IVF. As is customary in our IVF unit, 24, 72 and 96 hours after oocyte retrieval, the embryos will by studied by an embryologist for the number of cells and embryo quality.

02

Conditions studied

  • Infertility, Female

Keywords

  • ICSI
  • IVF
  • Infertility
  • non-male factor
  • intracytoplasmic sperm injection
  • In vitro fertilization
03

Who can participate

Ages eligible
39 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Women between 39 to 44 years of age undergoing IVF treatments for non-male factor infertility.

Exclusion criteria

Exclusion Criteria:

  • Women undergoing IVF treatments for male factor infertility.
  • Cases where PGD is planned.
  • Women with a BMI above 40.
  • Women younger then 39 years of age or older then 44 years of age.
  • Women with a rate of fertilization bellow 50% in previous IVF cycles.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    ICSI

    All the oocytes in this group (from one ovary) will undergo insemination by ICSI.

    Other: ICSI

  • Active comparator
    Conventional IVF

    All the oocytes in this group (from the other ovary) will undergo insemination by conventional IVF.

    Other: Conventional IVF

Interventions

  • OtherICSI

    Oocytes retrieved from one ovary will undergo insemination by ICSI.

  • OtherConventional IVF

    Oocytes retrieved from the second ovary will undergo insemination by conventional IVF

05

What researchers measure

Primary outcomes

  1. Fertilization rate

    The rate of fertilized oocytes

    Time frame: 1 day

Secondary outcomes

  1. Embryos

    Number of embryos day 2/3

    Time frame: 3-4 day

  2. Top quality embryos

    Number of top quality embryos day 2/3. Embryos will be defined as top quality if they will have four cells on Day 2 and/or 7 or 8 cells on Day 3, contain \<20% fragmentation, and exhibited no apparent morphological abnormalities.

    Time frame: 3-4 days

  3. Pregnancy

    Pregnancy is defined as positive βhCG blood test 11-14 days after embryo transfer.

    Time frame: Approximately 2 weeks

  4. Clinical pregnancy

    Clinical pregnancy is defined as gestational sac seen on vaginal ultrasound scan by 6 weeks gestation.

    Time frame: Approximately 6 weeks

  5. Pregnancy above 8 weeks gestation

    Pregnancy above 8 weeks gestation with the appreance of a fetal pulse

    Time frame: Approximately 8 weeks

06

Study locations

1 site
  • IVF Unit, Sheba medical Center
    Tel HaShomer, Israel
07

References and documents

Publications

  • Palermo G, Joris H, Devroey P, Van Steirteghem AC. Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet. 1992 Jul 4;340(8810):17-8. doi: 10.1016/0140-6736(92)92425-f. PubMed 1351601 ↗
  • Boulet SL, Mehta A, Kissin DM, Warner L, Kawwass JF, Jamieson DJ. Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. JAMA. 2015 Jan 20;313(3):255-63. doi: 10.1001/jama.2014.17985. PubMed 25602996 ↗
  • Bhattacharya S, Hamilton MP, Shaaban M, Khalaf Y, Seddler M, Ghobara T, Braude P, Kennedy R, Rutherford A, Hartshorne G, Templeton A. Conventional in-vitro fertilisation versus intracytoplasmic sperm injection for the treatment of non-male-factor infertility: a randomised controlled trial. Lancet. 2001 Jun 30;357(9274):2075-9. doi: 10.1016/s0140-6736(00)05179-5. PubMed 11445099 ↗
  • Check JH, Yuan W, Garberi-Levito MC, Swenson K, McMonagle K. Effect of method of oocyte fertilization on fertilization, pregnancy and implantation rates in women with unexplained infertility. Clin Exp Obstet Gynecol. 2011;38(3):203-5. PubMed 21995144 ↗
  • Luna M, Bigelow C, Duke M, Ruman J, Sandler B, Grunfeld L, Copperman AB. Should ICSI be recommended routinely in patients with four or fewer oocytes retrieved? J Assist Reprod Genet. 2011 Sep;28(10):911-5. doi: 10.1007/s10815-011-9614-9. Epub 2011 Jul 27. PubMed 21792665 ↗
  • Fishel S, Aslam I, Lisi F, Rinaldi L, Timson J, Jacobson M, Gobetz L, Green S, Campbell A, Lisi R. Should ICSI be the treatment of choice for all cases of in-vitro conception? Hum Reprod. 2000 Jun;15(6):1278-83. doi: 10.1093/humrep/15.6.1278. PubMed 10831555 ↗
  • Korkmaz C, Tekin YB, Sakinci M, Ercan CM. Effects of maternal ageing on ICSI outcomes and embryo development in relation to oocytes morphological characteristics of birefringent structures. Zygote. 2015 Aug;23(4):550-5. doi: 10.1017/S0967199414000197. Epub 2014 May 29. PubMed 24869767 ↗
  • Tannus S, Son WY, Gilman A, Younes G, Shavit T, Dahan MH. The role of intracytoplasmic sperm injection in non-male factor infertility in advanced maternal age. Hum Reprod. 2017 Jan;32(1):119-124. doi: 10.1093/humrep/dew298. Epub 2016 Nov 16. PubMed 27852688 ↗
  • Haas J, Miller TE, Nahum R, Aizer A, Kirshenbaum M, Zilberberg E, Lebovitz O, Orvieto R. The role of ICSI vs. conventional IVF for patients with advanced maternal age-a randomized controlled trial. J Assist Reprod Genet. 2021 Jan;38(1):95-100. doi: 10.1007/s10815-020-01990-5. Epub 2020 Oct 28. PubMed 33118102 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03370068
Lead sponsor
Dr. Tal Miller-Elkan
Responsible party
Dr. Tal Miller-Elkan (Principal Investigator, Sheba Medical Center) — Sponsor-investigator
First posted
Dec 12, 2017
Start date
Jan 1, 2018
Primary completion
Jul 1, 2020
Completion
Jul 1, 2020
Last update
Jul 28, 2020

Study contacts

Tal TE Elkan Miller, MD PhD
principal investigator · Sheba Medical Cente

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion